Opthea Ltd has released a press release.
Opthea Doses First Patients in Australia for Phase 2a in DME
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Opthea
- Opthea presents Ph1/2a wAMD data at Retina Society Meeting
- Opthea Receives Positive Safety Review for Ph2b wAMD Trial
- Opthea Appendix 4E and Annual Report 2018
- Opthea Doses First Patient in Ph2a Trial for OPT-302 in DME
- Opthea Meets Primary Safety Objective in DME Phase 1b trial
Later from Opthea
- Opthea CEO Presentation of Trial Updates at OIS@AAO 2018
- Opthea Receives A$12m R&D Tax Incentive
- Opthea Phase 2b wAMD trial fully recruited ahead of schedule
- Opthea confirms final patient enrolment in Ph2b wAMD trial
- Opthea Options Exercise Generates Proceeds of A$13.3m
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea